HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAapproval83% confidence

Understanding the Risks of Compounded Drugs

Source: FDA

Why This Matters

Why this matters: illustrates how regulators handled a comparable approval decision relevant to Roche.

Regulatory Analysis

Compounded drugs are not FDA-approved. This means the agency does not verify their safety, effectiveness or quality before they are marketed. Learn more.

Supporting Context

Therapeutic area
Infectious Diseases · Tuberculosis
Sub-indication
General

Related signal: Roche's Elecsys IGRA TB Test Receives CE Mark for Tuberculosis Detection

Source

View source document

Related Signal

Open signal — Roche's Elecsys IGRA TB Test Receives CE Mark for Tuberculosis Detection
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.